Inactivation of ataxia telanglectasia mutated gene in B-cell chronic lymphocytic leukaemia

Lancet

Volumn 353, Issue 9146, 1999, Pages 26-29

  Stankovic, Tatjana ^a   Weber, Peter ^a   Stewart, Grant ^a   Bedenham, Tina ^a   Murray, Jim ^a   Byrd, Phil J ^a   Moss, Paul A H ^a   Taylor, A Malcolm R ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RESTRICTION ENDONUCLEASE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; VAP CYCLO PROTOCOL; VAP-CYCLO PROTOCOL; VINCRISTINE;

ALLELE; APOPTOSIS; ARTICLE; ATAXIA TELANGIECTASIA; B CELL LEUKEMIA; CELL SURVIVAL; CLINICAL ARTICLE; DNA DETERMINATION; DNA FINGERPRINTING; FEMALE; GENE DELETION; GENE FREQUENCY; GENE INACTIVATION; GENE INSERTION; GENE MUTATION; GENE SEQUENCE; GENETIC SUSCEPTIBILITY; HETEROZYGOTE; HUMAN; IMMUNOBLOTTING; LYMPHATIC LEUKEMIA; MALE; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; CHROMOSOME 11; GENETIC PREDISPOSITION; GENETICS; MUTATION; TANDEM REPEAT; WESTERN BLOTTING;

ALLELES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATAXIA TELANGIECTASIA; BLOTTING, WESTERN; CHROMOSOMES, HUMAN, PAIR 11; CYCLOPHOSPHAMIDE; DNA FINGERPRINTING; DNA RESTRICTION ENZYMES; DOXORUBICIN; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; LEUKEMIA, B-CELL; MALE; MUTATION; PREDNISOLONE; TANDEM REPEAT SEQUENCES; VINCRISTINE;

EID: 0033513587     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)10117-4     Document Type: Article

References (25)

1. Rozman C., Monserrat E. Chronic lymphocytic leukemia. N Engl J Med. 333:1995;1052-1059.
2. Schena M., Larsson L.G., Gottardi Det al. Growth-and-differentiation-associated expression of bcl-2 in B chronic lymphocytic leukaemia cells. Blood. 79:1992;2981-2989.
3. Mariano M.T., Moretti L., Donelli Aet al. Bcl-2 gene expression in haematopoietic cell differentiation. Blood. 80:1992;768-775.
4. Lens D., Dyer M.J., Garcia-Marco JMet al. p53 abnormalities in CLL are associated with excess of prolymphocytes and poor prognosis. Br J Haematol. 99:1997;848-857.
5. Cordone I., Masi S., Mauro FRet al. p53 expression in B cell chronic lymphocytic leukemia. Blood. 91:1998;4342-4349.
6. Bullrich F., Veronese M.I., Kitada Set al. Minimal region of loss at 13q14 in B cell chronic lymphocytic leukemia. Blood. 88:1996;3109-3115.
7. Fegan C., Robinson H., Thompson P., Whittaker J.A., White D. Karyotypic evolution in CLL. Leukaemia. 9:1995;2003-2008.
8. Stilgenbauer S., Liebisch P., James MRet al. Molecular cytogenetic delineation of a novel critical genomic region in chromosome bands 11q22-23 in lymphoproliferative disorders. Proc Natl Acad Sci USA. 93:1996;11837-11841.
9. Neilson A.R., Auer R., White Det al. Deletions at 11q identify a subset of patients with typical CLL who show consistent disease progression and reduced survival. Leukaemia. 11:1997;1929-1932.
10. Savitsky K., Bar-Shira A., Gilad Set al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science. 268:1995;1749-1753.
11. Westphal C.H., Rowan S., Schmaltz C., Elson A., Fisher D.E., Leder P. atm and p53 cooperate in apoptosis and suppression of tumorigenesis but not in resistance to acute radiation toxicity. Nat Genet. 16:1997;397-401.
12. Taylor A.M.R., Metcalfe J.A., Thick J., Mak Y-F Leukemia and lymphoma in ataxia telangiectasia. Blood. 87:1996;423-438.
13. Vorechovsky I., Luo L., Dyer MJSet al. Clustering of missense mutations in the ataxia telangiectasia gene in a sporadic T cell leukaemia. Nat Genet. 17:1997;96-99.
14. Stilgenbauer S., Schaffner C., Litterst Aet al. Biallelic mutations in the ATM gene in T-prolymphocytic leukaemia. Nat Med. 3:1997;1155-1159.
15. Stoppa-Lyonnet D., Soulier J., Lauge Aet al. Inactivation of the ATM gene in T-cell prolymphocytic leukemia. Blood. 91:1998;3920-3926.
16. Stankovic T., Kidd A.M.J., Sutcliffe Aet al. ATM mutations and phenotypes in A-T families in the British Isles. Am J Hum Genet. 62:1998;334-345.
17. Liu Q., Sommer S.S. Restriction endonuclease fingerprinting (REF). BioTechniques. 18:1995;470-477.
18. Byrd P.J., McConville C.M., Cooper Pet al. Mutations revealed by sequencing the 5′ half of the gene for ataxia telangiectasia. Hum Mol Genet. 5:1996;145-149.
19. Vorechovsky I., Rasio D., Luo Let al. The ATM gene and susceptibility to breast cancer. Cancer Res. 56:1996;2726-2732.
20. Starostik P., Manshouri T., O'Brien Set al. Deficiency of the ATM protein defines an aggressive subgroup of B-cell chronic lymphocytic leukemia. Cancer Res. 58:1998;4552-4557.
21. Easton D.F. Cancer risks in A-T heterozygotes. Int J Radiat Biol. 6:1994;S177-182.
22. Fraumeni J.F., Vogel C.L., DeVita V.T. Familial chronic lymphocytic leukemia. Ann Intern Med. 71:1969;279-284.
23. Spector BD, Filipovich AH, Pery GS, Kersey KS. Epidemiology of cancer in ataxia telangiectasia. In: Bridges BA, Harnden DF, eds. Ataxia telangiectasia. Chichester: Wiley, 1982: 103-38.
24. Matutes E., Brito-Babapulle V., Swansbury Jet al. Clinical and laboratory features of 78 cases of T cell prolymphocytic leukemia. Blood. 78:1991;3269-3274.
25. Luo L.P., Lu F.M., Hart Set al. Ataxia-telangiectasia and T-cell leukemias. Cancer Res. 58:1998;2293-2297.